Related Experiment Video
Updated: Jun 17, 2026
07:38
Generating Acute and Chronic Experimental Models of Motor Tic Expression in Rats
Published on: May 27, 2021
Glutamatergic modulatory therapy for Tourette syndrome
Harvey S Singer1, Christina Morris, Marco Grados
1Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. hsinger@jhmi.edu
Medical Hypotheses
|December 22, 2009
Summary
Tourette syndrome (TS) treatments are limited. Glutamate modulators show promise for tic suppression, potentially offering a new therapeutic avenue for this neuropsychiatric disorder.
Area of Science:
- Neuroscience
- Pharmacology
- Genetics
Background:
- Tourette syndrome (TS) is a neuropsychiatric disorder causing motor and vocal tics.
- Common comorbidities include OCD, ADHD, anxiety, and depression.
- Current TS treatments have limited efficacy and side effects.
Purpose of the Study:
- To explore glutamate modulators as a novel therapeutic strategy for Tourette syndrome.
- To review evidence supporting glutamate's role in TS pathophysiology.
- To assess potential treatments targeting the glutamate system.
Main Methods:
- Review of scientific literature on glutamate's role in cortico-striatal-thalamo-cortical (CSTC) circuits.
- Analysis of genetic and neurochemical studies in TS.
- Examination of glutamate modulator efficacy in related disorders like OCD.
Main Results:
- Glutamate plays a key role in CSTC circuits implicated in TS.
- Interactions between glutamate and dopamine systems are significant in TS.
- Evidence from genetic and postmortem studies suggests altered glutamatergic function.
Conclusions:
- Modulating the glutamate system offers a potential new pharmacological approach for TS.
- Further research is needed to clarify the hyper- or hypo-glutamatergic state in TS.
- Glutamate antagonists or agonists may provide novel tic-suppressing therapies.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Cholinergic Antagonists: Therapeutic Uses
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.